TrialPloS one2017

Hypofractionated stereotactic boost in intermediate risk prostate carcinoma: Preliminary results of a multicenter phase II trial (CKNO-PRO).

David Pasquier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.